我們已在上線！進一步了解

ProKidney

PROK

市值 US$2.78億

1.33 USD

-0.13

8.9%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

1.32

-0.01

0.75%

1天

-8.9%

5天

-22.22%

1個月

-28.11%

3個月

-17.39%

6個月

-31.79%

今年迄今

-40.36%

1年

-56.25%

5年

-86.46%

10年

-86.84%

關於： ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

員工： 231

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 0%

中性 25%

負面 75%

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026

WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the Company will present eight abstracts, including one oral presentation, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held from October 21-25, 2026, in Denver, CO.

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026

20 stocks likely to lose money even if the bull market continues

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

20 stocks likely to lose money even if the bull market continues

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK's cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising 'going concern' doubts.

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

Zacks Investment Research

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

ProKidney Appoints Kenneth Locke as Chief Technical Officer

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization of rilparencel

ProKidney Appoints Kenneth Locke as Chief Technical Officer

Zacks Investment Research

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Corp. (PROK) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

WINSTON-SALEM, N.C., May 15, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the first quarter ended March 31, 2026, and provided business highlights.

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

WINSTON-SALEM, N.C., March 25, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced the appointment of Greg Madison as Chief Commercial Officer.

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

PROK's main value driver is Rilparencel, which is now in a pivotal trial called PROACT 1. The FDA also accepted using eGFR slope analysis for evaluating its potential accelerated approval. PROK believes they'll be ready with their topline slope analysis by Q2 2027. So, there's a clearly outlined regulatory pathway for PROK at this point.

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

查看新聞排名

價格圖表採用Lightweight Charts™實作